Multiple Sclerosis Clinical Trial

Clinical Trial Finder Multiple Sclerosis Trials

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

See Locations Near You

Summary

The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis. This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).

View Full Description

Full Description

Botulinum toxin Type A 300U has been discontinued from the study. Patients remaining in the arm containing botulinum toxin Type A 300U will receive botulinum toxin Type A 200U moving forward. Also, the masking of the study is now open-label.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient has participated in study 191622-515 or 191622-516 and the following criteria fulfilled:

Patient completed at least 52 weeks in the preceding study.
No longer than 6 months has elapsed since completion of the preceding study
Patient has not received any prohibited medications during any intervening period between the preceding study and this long-term study.

Exclusion Criteria:

History or evidence of pelvic or urologic abnormality.
Previous or current diagnosis of bladder or prostate cancer.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

397

Study ID:

NCT00876447

Recruitment Status:

Completed

Sponsor:

Allergan

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You


Middlebury Connecticut, , United States

Randwick , , Australia

Innsbruck , , Austria

Ghent , , Belgium

Rio de Janeiro , , Brazil

Victoria British Columbia, , Canada

Ostrava , , Czechia

Salouel , , France

Kiel , , Germany

Florence , , Italy

Amsterdam , , Netherlands

Epsom , , New Zealand

Poznan , , Poland

Porto , , Portugal

Moscow , , Russian Federation

Singapore , , Singapore

Presov , , Slovakia

Pretoria , , South Africa

Tenerife , , Spain

Hualien , , Taiwan

Kiev , , Ukraine

London , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 3

Estimated Enrollment:

397

Study ID:

NCT00876447

Recruitment Status:

Completed

Sponsor:


Allergan

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider